Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Biogen (BIIB)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Centene (CNC – Research Report) and Biogen (BIIB – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Centene (CNC)
Bank of America Securities analyst Kevin Fischbeck reiterated a Sell rating on Centene on February 6 and set a price target of $32.00. The company’s shares closed last Friday at $38.46.
According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Centene with a $43.75 average price target.
See today’s best-performing stocks on TipRanks >>
Biogen (BIIB)
Citi analyst Geoff Meacham maintained a Hold rating on Biogen on February 6 and set a price target of $215.00. The company’s shares closed last Friday at $201.18.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $194.85 average price target, implying a 4.2% upside from current levels. In a report released yesterday, TipRanks – OpenAI also downgraded the stock to Hold with a $215.00 price target.
